Singapore markets closed

Straits Times Index
3,297.55
-26.98(-0.81%)
Nikkei
38,814.56
+94.09(+0.24%)
Hang Seng
17,941.78
-170.85(-0.94%)
FTSE 100
8,146.86
-16.81(-0.21%)
Bitcoin USD
66,120.30
+819.91(+1.26%)
CMC Crypto 200
1,404.03
-13.84(-0.98%)

AMGN Mar 2025 195.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

2.0000

-0.3000

(-13.04%)

At close: 12:56PM EDT

PR Newswire
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
Zacks
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.
Zacks
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in first-half 2026